Clinical and molecular features of a TSH-secreting pituitary microadenoma

被引:11
作者
Usui T. [1 ]
Izawa S. [2 ]
Sano T. [3 ]
Tagami T. [2 ]
Nagata D. [1 ]
Shimatsu A. [2 ]
Takahashi J.A. [4 ]
Naruse M. [1 ]
机构
[1] Department of Endocrinology, Clinical Research Institute, Kyoto
[2] Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto
[3] Department of Human Pathology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima
[4] Department of Neurosurgery, Kyoto University, Faculty of Medicine
关键词
RT-PCR; Somatostatin receptor; Thyroid hormone receptor; Transcription factor; Transcriptional cofactor; TSH-secreting adenoma;
D O I
10.1007/s11102-005-3759-4
中图分类号
学科分类号
摘要
We describe a case of a thyroid stimulating hormone (TSH)-secreting pituitary microadenoma, and report the systematic gene expression profile of the surgically- removed tumor. A 50-year-old woman was referred to our hospital because she had high TSH, free-T4, and free-T3 levels, and a pituitary tumor that was visualized with magnetic resonance imaging. Her basal TSH level was high even after a high T3 loading dose, and increased following administration of thyroid releasing hormone (TRH) even after administration of a high dose of exogenous T3. Her clinical symptoms and peripheral markers for T3 were responsive to exogenous T3. There was no thyroid hormone receptor (TR) β gene mutation. The patient was diagnosed with a TSH-secreting pituitary adenoma, and trans-sphenoid surgery was performed. The histologic features and immunophenotype were consistent with a TSH-secreting pituitary adenoma. Reverse transcription-polymerase chain reaction analysis of pituitary hormones, pituitary-specific transcription factors, receptors, and transcriptional cofactors of clinical significance was performed on the removed tumor. The tumor expressed TSH, growth hormone, prolactin, α-subunit, pituitary transcription factor-1 (pit-1) but not proopiomelanocortin (POMC), prophet of pit-1 (prop-1) and pituitary cell-restricted T box factor (Tpit). TRβ and TRH-receptor gene expression was normal. Three steroid receptor coactivators (SRC)-1, SRC-2, and SRC-3 were expressed. Nuclear receptor corepressor (N-CoR)2 was absent in the tumor, whereas nuclear receptor corepressor (N-CoR1) was expressed. Somatostatin receptor type 1 expression was significantly decreased, whereas type 4 receptor was expressed, which are unusual characteristics for pituitary tumors. The gene expression pattern in the tumor might have a role in the clinical features of this case. © 2005 Springer Science + Business Media, Inc.
引用
收藏
页码:127 / 134
页数:7
相关论文
共 24 条
[1]  
Beck-Peccoz P., Brucker-Davis F., Persani L., Smallridge R.C., Weintraub B.D., Thyrotropin-secreting pituitary tumors, Endocr Rev, 17, pp. 610-638, (1996)
[2]  
Brucker-Davis F., Oldfield E.H., Skarulis M.C., Doppman J.L., Weintraub B.D., Thyrotropin-secreting pituitary tumors: Diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health, J Clin Endocrinol Metab, 84, pp. 476-486, (1999)
[3]  
Akiyoshi F., Okamura K., Fujikawa M., Sato K., Yoshinari M., Mizokami T., Hattori K., Kuwayama A., Takahashi Y., Fujishima M., Difficulty in differentiating thyrotropin secreting pituitary microadenoma from pituitary-selective thyroid hormone resistance accompanied by pituitary incidentaloma, Thyroid, 6, pp. 619-625, (1996)
[4]  
Safer J.D., Colan S.D., Fraser L.M., Wondisford F.E., A pituitary tumor in a patient with thyroid hormone resistance: A diagnostic dilemma, Thyroid, 11, pp. 281-291, (2001)
[5]  
Refetoff S., Weiss R.E., Usala S.J., The syndromes of resistance to thyroid hormone, Endocr Rev, 14, pp. 348-399, (1993)
[6]  
Weiss R.E., Tunca H., Knapple W.L., Faas F.H., Refetoff S., Phenotype differences of resistance to thyroid hormone in two unrelated families with an identical mutation in the thyroid hormone receptor beta gene (R320C), Thyroid, 7, pp. 35-38, (1997)
[7]  
Jameson J.L., Mechanisms by which thyroid hormone receptor mutations cause clinical syndromes of resistance to thyroid hormone, Thyroid, 4, pp. 485-492, (1994)
[8]  
Aron D.C., Howlett T.A., Pituitary incidentalomas, Endocrinol Metab Clin North Am, 29, pp. 205-221, (2000)
[9]  
Sanno N., Oyama K., Tahara S., Teramoto A., Kato Y., A survey of pituitary incidentaloma in Japan, Eur J Endocrinol, 149, pp. 123-127, (2003)
[10]  
Dong Q., Brucker-Davis F., Weintraub B.D., Smallridge R.C., Carr F.E., Battey J., Spiegel A.M., Shenker A., Screening of candidate oncogenes in human thyrotroph tumors: Absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes, J Clin Endocrinol Metab, 81, pp. 1134-1140, (1996)